Latest Quarterly Report
Filed: 2026-04-30
Key Insights
- The filing is dated April 30, 2026 for Q1 2026 (ended March 31, 2026), containing standard XBRL formatted financial data across three business segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals.
- The document references multiple material items including derivative instruments, hedging activities, discontinued operations, property and equipment valuations, and various intangible assets including customer relationships, patents, and trade names.
- The filing shows continued activities related to kidney care transition services and manufacturing agreements (referenced with January 31, 2025 dates), along with environmental cleanup obligations at Superfund sites and ethylene oxide exposure matters requiring ongoing disclosure.
- Baxter maintains a revolving credit facility and commercial paper program as of March 31, 2026, with accumulated other comprehensive income adjustments including translation adjustments, defined benefit plan adjustments, and cash flow hedge impacts tracked across multiple reporting periods.